Form 4: Eli Lilly Executive Reports Stock Sale and Correction of Prior Grant Omission

A recent SEC filing reveals that Eli Lilly's SVP of Finance and CAO, Donald A. Zakrowski, sold 750 shares of common stock and corrected a previous omission of restricted stock unit grants.

Summary

• Donald A. Zakrowski, SVP of Finance and CAO at Eli Lilly, reported a sale of 750 shares of common stock at a price of $753.6 per share on March 11, 2024.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 16, 2023.
• The filing also corrects an omission from a previous Form 4 filed on February 14, 2024, regarding the grant of restricted stock units.
• Specifically, 184 restricted stock units were granted on February 12, 2024, exercisable on February 16, 2026, and another 186 restricted stock units were granted on the same date, exercisable on February 16, 2027.
• Following these transactions, Zakrowski directly owns 7,880 shares of common stock and indirectly owns 1,710 shares through a 401(k) plan.
• He also directly owns 184 restricted stock units exercisable in 2026 and 186 restricted stock units exercisable in 2027.

Sentiment

Score: 6

Explanation: The document reflects routine insider trading activity and a minor correction, which is neither significantly positive nor negative. The use of a 10b5-1 plan suggests the sale was planned and not based on any new information.

Risks

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it was conducted under a pre-arranged trading plan.
• The need to correct a previous filing may raise questions about internal controls, although the correction was made promptly.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for executives of publicly traded companies. The use of a Rule 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The reporting of stock transactions by executives is a standard practice across all publicly listed companies, including pharmaceutical giants like Pfizer (PFE) and Johnson & Johnson (JNJ).
• The use of Rule 10b5-1 trading plans is also a common practice among executives at these companies to manage their stock sales in a compliant manner.
• The correction of a previous filing, while not ideal, is not uncommon and demonstrates a commitment to transparency, similar to what is expected from other large cap companies.

Stakeholder Impact

• The stock sale by an executive could have a minor negative impact on shareholder sentiment, although the use of a 10b5-1 plan mitigates this concern.
• The correction of the previous filing demonstrates a commitment to transparency, which is positive for stakeholders.

Key Dates

Keywords

insider trading, SEC Form 4, stock sale, restricted stock units, Rule 10b5-1, Eli Lilly, LLY, executive compensation